MedTrace Logo

The Use of Islet Organoids in the Treatment of Pancreatic Surgery-related Diabetes

NCT06415643 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2024-07-30

No results posted yet for this study

Summary

The purpose of this clinical trial is to verify the safety and effectiveness of autologous islet organoids transplantation after in vitro expansion for the treatment of pancreatogenic diabetes.

Conditions

  • T3c Diabetes

Interventions

OTHER

Islet organoids transplantation

autologous transplantation of ex vivo expanded islet organoids.

Sponsors & Collaborators

  • Newislet Biotechnology (Shanghai) Ltd.

    collaborator UNKNOWN

  • Zhejiang University

    lead OTHER

Principal Investigators

  • Sheng Yan, PhD, MD · Zhejiang University Second Affiliated Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-10
Primary Completion
2025-12-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06415643 on ClinicalTrials.gov